IV Ozone Therapy: Not Recommended
Intravenous ozone therapy should not be used in clinical practice due to lack of proven efficacy, absence of regulatory approval, and documented risk of severe neurological complications including ischemic stroke, encephalopathy, and death.
Evidence-Based Rationale
Guideline Recommendations Against Use
The most recent and authoritative guidelines explicitly recommend against ozone therapy:
The 2024 IWGDF (International Working Group on the Diabetic Foot) guidelines provide a strong recommendation (Grade: Strong; Certainty: Low) to NOT use ozone therapy for wound healing in diabetic foot ulcers 1. The guideline grouped ozone with "other gases" and found all studies were at high risk of bias with no demonstrable clinical benefit 1.
The evidence supporting ozone was rated as "very low certainty" with trivial desirable effects and an unfavorable balance of effects compared to standard care 1.
Documented Safety Concerns
Recent case reports reveal serious neurological complications:
A 2025 case documented severe neurological crisis following IV ozone therapy in a previously healthy 36-year-old woman, resulting in multiple ischemic infarcts in the thalamus and cerebellum, seizures, syncope, ICU admission, and lasting cognitive impairments requiring long-term rehabilitation 2.
A 2025 case of ozone-induced encephalopathy following subcutaneous injection required mechanical ventilation for 48 hours, though symptoms eventually resolved 3.
The therapeutic window is dangerously narrow: beneficial effects claimed at 10-40 µg/mL, but potential toxicity at doses >80 µg/mL 4.
Lack of High-Quality Clinical Evidence
The 2026 umbrella review of systematic reviews examining ozone therapy across multiple conditions found 5:
- All evidence was rated as low or very low certainty
- Studies were predominantly small, heterogeneous, and methodologically flawed
- No consistent benefit demonstrated across clinical conditions
- Safety outcomes inconsistently reported
- Routine clinical use is not justified
Regulatory Status
The U.S. FDA has not approved ozone therapy for medical use and warns against it due to toxic properties and lack of proven benefits at tolerable exposure levels 2.
Ozone therapy remains controversial within evidence-based medicine with limited regulatory acceptance globally 6.
Clinical Context
While some experimental studies suggest potential mechanisms (ROS generation, immunomodulation), these have not translated into clinically meaningful outcomes 6:
- The 2023 review on COVID-19 applications showed mixed results with no mortality benefit 7
- A 2021 pilot study in COVID-19 patients was uncontrolled and lacked rigorous methodology 8
- The 2026 review concluded ozone should be regarded as "investigational and adjunctive" rather than validated therapy 6
Common Pitfalls to Avoid
- Do not confuse topical oxygen therapy with ozone therapy - they are entirely different interventions with different evidence bases
- Do not be misled by mechanistic plausibility - biological effects in vitro do not equal clinical efficacy
- Do not consider ozone therapy as "alternative" or "complementary" - it carries real risks without proven benefits
- Recognize that >95% of positive studies are animal models that have failed to translate to humans 4
Bottom Line
There is no clinical indication for IV ozone therapy in current medical practice. The combination of strong guideline recommendations against use, documented serious adverse events including stroke and encephalopathy, lack of high-quality supporting evidence, and absence of regulatory approval makes this an unsafe and ineffective intervention that should be avoided 1, 2, 5, 6.